THE WALL STREET JOURNAL reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda(R)"
Read more here.
American Pharmaceutical Review presented, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"
proactive reported, "Noxopharm files patent for Veyonda® as treatment for septic shock."
Noxopharm patent to protect use of drug candidate beyond cancer into septic shock.
Australian digital pharmaceutical news site, Health Industry Hub reported, "Noxopharm and BMS immuno-oncology trial proceeds to patient recruitment"
In its conference data report for the ASCO Genitourinary Cancers Symposium, BioWorld reported on Noxopharm.
Bloomberg Business reported, “Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference”.
PharmaVOICE.com, the digital resource for life-sciences executives and other healthcare-service related professionals provided the following.
Digital hub for Life Science industry news, BioSpace, shared the following release after the ASCO GU Cancers Symposium.
Biotech Dispatch, a news site dedicated to the breaking news and commentary about the Australian biotechnology and Life Sciences sector reported.
AddressLevel 4, 828 Pacific Highway Gordon. 2072 NSW AUSTRALIA
PO Box 292, Gordon
2072 NSW AUSTRALIA
50 608 966 123
Join our mailing list to receive the latest information from Noxopharm Limited